Characteristics Overall (n=214) Unifocal cases (n-143) Multifocal cases (n=71) p-value
Age at Diagnosis 62.8 (45-74) 62.6 (45-74) 63.4 (52-74) 0.066
PSA at Diagnosis <4 ng/ml 12 (6.1) 7 (5.4) 5 (7.2) 0.283
4-10 ng/ml 111 (56.1) 75 (58.1) 36 (52.2)
>10 ng/ml 75 (37.9) 47 (36.4) 28 (40.6)
n/a 16 14 2
Gleason Score 2-6 50 (23.4) 33 (23.1) 17 (23.9) 0.221
3+4 56 (26.2) 34 (23.8) 22 (31.0)
4+3 83 (38.8) 59 (41.3) 24 (33.8)
8-10 25 (11.7) 17 (11.9) 8 (11.3)
pT-stage T1a 1 (0.5) 1 (0.7) 0 (0) 0.92
T1b 6 (2.8) 4 (2.7) 2 (2.8)
T1c 111 (51.9) 73 (51.0) 38 (53.5)
T2 85 (39.7) 59 (41.3) 26 (36.6)
T3 11 (5.1) 6 (4.2) 5 (7.0)
R-status R0 102 (47.7) 71 (49.7) 31 (43.7) 0.697
R1 49 (22.9) 32 (22.4) 17 (23.9)
RX 63 (29.4) 40 (28) 23 (32.4)
CRPC Yes 16 (8.0) 13 (10.0) 3 (4.3) 0.095
No 183 (92.0) 117 (90.0) 66  (95.7)
n/a 15 13 2
PCA specific Death Yes 15 (7.5) 11 (8.4) 4 (5.8) 1
No 185 (92.5) 120 (91.6) 65 (94.2)
n/a 14 12 2
PCA relapse Yes 55 (29.4) 37 (30.3) 18 (27.7) 0.241
No 132 (70.6) 85 (69.7) 47 (72.3)
n/a 27 21 6
Secondary treatment Radiation 25 (11.7) 18 (12.6) 7 (9.9) 0.059
Hormonal 42 (19.6) 31 (21.7) 2 (2.8) 0.283
Radiation+Hormonal 8 (3.8) 6 (4.2) 2 (2.8) 1
Table 1: Selected characteristics of the study cohort